2. 2022 EBMT ABSTRACT OS08-02 PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): 1-YEAR FOLLOW-UP OF ZUMA-1 COHORT 6 (C6...
19.0% (8/42), respectively, with 59.1% (13/22) and 31.8% (7/22) in the nab‐paclitaxel cohort and 30.0% (6/20) and 5.0% (1/20) in paclitaxel cohorts. The most common treatment‐related adverse events (TRAEs) were anemia (89.1%) and alopecia (71.7%), and no significant differenc...
In cohort 1, 34 (85.0%) of 40 patients had discontinued the treatment by the cutoff date, and 6 (15.0%) patients remained on treatment (Fig. 1C and Supplementary Fig. 1). Twenty-two (64.7%) of the 34 patients were discontinued because of disease progression, and one (2.9%) patient ...
In our findings, the combination of HAIC with camrelizumab and apatinib was generally well-tolerated. The frequency and severity of AEs encountered in our cohort aligned with the established safety profiles of HAIC and the combination of camrelizumab and apatinib, as indicated in prior researc...
Cohort 1: R/R extranodal NK/T-cell lymphoma (n = 22); cohort 2: R/R mature T-cell neoplasms (n = 44; 21 peripheral T-cell lymphoma not otherwise specified; 11 angioimmunoblastic T-cell lymphoma; 12 anaplastic large cell lymphoma); cohort 3: R/R cutaneous T-cell lymphomas (CTCL;...
5i). In a recent large cohort for NSCLC receiving immune checkpoint blockades,27 higher TYROBP expression tendency was also observed in responders (Supplementary Fig. 5j). Meanwhile, patients with higher TYROBP expression also showed better OS (P = 0.0016) and PFS (P = 0.00076) in ...
at risk (censored): 11 (0) 4 8 12 Time Since Treatment Initiation (months) 52 1 (6) (9) (10) 16 0 (11) Fig. 2 | Overall response and survival of PD-1 antagonist-resistant NPC (Cohort 2). A Waterfall plot of the best response in PD-1 antagonist-resistant NPC patients (n =...
Eight of the 15 patients (53.3%) experienced at least one serious adverse event, resulting in discontinuation of study for 6 (40%) patients. One patient had a bowel perforation. One patient (3 mg/kg cohort) experienced a treatment-related grade 5 cardiopulmonary arrest resulting in death. ...
A stage in our center, who underwent upfront curative resection during the simultaneous period as the trial was ongoing. Patients’ demographics, surgery characteristics and incidence of surgical complications were reviewed in this retrospective cohort and compared with the patients enrolled in the trial...
5i). In a recent large cohort for NSCLC receiving immune checkpoint blockades,27 higher TYROBP expression tendency was also observed in responders (Supplementary Fig. 5j). Meanwhile, patients with higher TYROBP expression also showed better OS (P = 0.0016) and PFS (P = 0.00076) in ...